Assay of Pro-angiogenic Cytokines in Exudative Age-Related Macular Degeneration
NCT ID: NCT03630562
Last Updated: 2022-04-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
100 participants
INTERVENTIONAL
2018-11-26
2021-08-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary goal of this study is to measure the aqueous humor concentration of pro-angiogenic cytokines in AMD patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD
NCT01213667
To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD)
NCT06888492
Effectiveness of Anti-VEGF Treatments in Wet AMD in Active Smokers
NCT04685369
Monocentric Retrospective Observational Study on Patients With Macular Degeneration
NCT02089503
A Study of EXG102-031 in Participants With wAMD
NCT06183814
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with exudative AMD
Aqueous humor samples collection
In addition to the routine examinations performed as part of the usual care of AMD patients, an anterior chamber puncture will be performed to collect the aqueous humor samples.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aqueous humor samples collection
In addition to the routine examinations performed as part of the usual care of AMD patients, an anterior chamber puncture will be performed to collect the aqueous humor samples.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of exudative age-related macular degeneration requiring intravitreal anti-VEGF treatment.
* Patient for whom the last intravitreal injection of anti-VEGF in the eye is strictly more than 3 months
* Signature of informed consent
* Affiliation to the French social security system
Exclusion Criteria
* Systemic treatment with anti-VEGF
* Intravitreal treatment with anti-VEGF for less than 3 months regardless of the treated eye.
* Retinal pathology that can modify the secretion of pro-inflammatory cytokines such as diabetic retinopathy, venous occlusions, intermediate and posterior uveitis.
* Diabetes Mellitus
* High Myopia
* Simultaneous participation in another clinical research protocol in exudative AMD
* Person under guardianship, under curatorship, deprived of liberty
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Nice
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Prof. Stéphanie BAILLIF, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Centre Hospitalier Universitaire de Nice
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Pasteur 2 - Service d'Ophtalmologie
Nice, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
17-PP-18
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.